Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

GlaxoSmithKline, in consultation with Health Canada, has issued a letter to healthcare professionals regarding ambrisentan [Volibris].

    • 13 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Contraindication regarding the use of VOLIBRIS (ambrisentan) in patients with Idiopathic Pulmonary Fibrosis (IPF). Internet Document: 9 Jul 2012. Available from: URL: http://www.hc-sc.gc.ca

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    GlaxoSmithKline, in consultation with Health Canada, has issued a letter to healthcare professionals regarding ambrisentan [Volibris].. React. Wkly. 1411, 4 (2012). https://doi.org/10.2165/00128415-201214110-00007

    Download citation

    Keywords

    • Public Health
    • Hypertension
    • Placebo
    • Connective Tissue
    • Placebo Group